Abstract #： 306-OR Presentation Form: Oral presentation Time: 2025 June 23, 14:15 PM – 14:30 PM（CST） Presenter: Dr. Lei Qian, Innovent Biologics Title: A novel antibody-peptide conjugate targeting ...

Novo Nordisk (NYSE: NVO) announced Thursday it will initiate Phase 3 trials for its experimental weight-loss drug amycretin in both injection and oral forms during the first quarter of 2026. The ...

Novo Nordisk said on Thursday it plans to start late-stage trials of its experimental weight-loss drug, amycretin, in ...

Tufts University scientists are aiming to revolutionize the future of weight loss drugs by engineering a new compound that ...

Regeneron signed a deal with China-based Hansoh Pharma for HS-20094, an investigational, late-stage anti-obesity asset. Per ...

Metsera is advancing promising obesity treatments with amylin and GLP-1 analogs, eyeing competitive efficacy and buyout ...

Global drugmakers, including generic drug manufacturers in India, are racing to develop their versions of blockbuster ...